REGISTER
NMPA Approves Depemokimab (Tezspire) for Chronic Rhinosinusitis with Nasal Polyps
China’s NMPA has approved GSK’s depemokimab for chronic rhinosinusitis with nasal polyps, making it the drug’s second approved indication in China after eosinophilic asthma and the first twice-yearly IL-5 monoclonal antibody cleared in the country for this disease. Supported by the Phase III ANCHOR studies, the approval highlights depemokimab’s efficacy in reducing polyp size and nasal obstruction while lowering treatment burden through ultra-long-acting dosing.

China's National Medical Products Administration (NMPA) approved GlaxoSmithKline's (GSK) depemokimab (brand name not yet confirmed for this indication) for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), marking the second approved indication for this ultra-long-acting biologic in China and the first twice-yearly interleukin-5 (IL-5) monoclonal antibody to receive regulatory clearance in the country for this disease.

GSK (United Kingdom) developed depemokimab as a next-generation anti-IL-5 monoclonal antibody characterized by an extended half-life, high binding affinity, and enhanced potency, enabling a twice-yearly subcutaneous dosing schedule. The regulatory submission was supported by two Phase III studies, ANCHOR-1 (N=271) and ANCHOR-2 (N=257), both of which met their co-primary endpoints. Compared with placebo, twice-yearly depemokimab produced statistically and clinically significant reductions in nasal polyp size and nasal obstruction scores. In a pooled analysis of secondary endpoints at Week 52, 74% of patients (n=200) in the depemokimab group and 64% of patients (n=164) in the placebo group had not required systemic corticosteroid (SCS) therapy, surgery, or disease-modifying treatment. When surgery or disease-modifying treatment alone was considered, 88% of depemokimab-treated patients (n=239) avoided these interventions versus 83% in the placebo group (n=213; p=0.146). The adverse event profile was comparable between treatment arms across both trials.

This approval represents the second indication granted to depemokimab in China—following its initial domestic approval for eosinophilic asthma in March 2026—and positions it as a potential successor to GSK's monthly IL-5 monoclonal antibody mepolizumab (Nucala®), which recorded global revenues of USD 2.651 billion in 2025. Depemokimab's extended dosing interval addresses an unmet clinical need for patients seeking reduced treatment burden. GSK is additionally evaluating depemokimab in Phase III trials for chronic obstructive pulmonary disease and eosinophilic granulomatosis with polyangiitis, signaling continued pipeline expansion in the IL-5 pathway.

0
0
Loading